either under stereotactic or ultrasound guidance with high effectiveness and safety. It has been shown that it is a good alternative to core needle biopsy (CB) and vacuum assisted biopsy (VAB) techniques with similar accuracy and complication rates. The underestimation rates of the technique are also comparable to those of VAB regarding high-risk lesions and ductal carcinoma in situ (DCIS).

Moreover, due to its unique advantage of excising an intact piece of breast tissue with preserved tissue margins, the effectiveness of the
Breast lesion excision system (BLES)

The biopsy equipment consisted of the Fischer prone digital stereotactic device (Mammotest; Fischer Imaging) and the BLES device (Breast Lesion Excision System® -B.L.E.S.-; Intact Medical).

All BLES biopsies were performed with an 8-gauge probe and 20 mm baskets by two experienced radiologists working in the department with 8 and 3 years of experience, respectively. All patients were placed in a prone position.

The procedure has been previously described in reports from our department. Briefly, after careful stereotactic localization of the targeted area in order to be centrally positioned, 20 ml of local anesthetic (lidocaine 2%) is applied around the area (12, 3, 6 and 9 o’clock positions). A post anesthesia stereotactic image is then taken to assess the accuracy of the positioning. In case of deviation of the targeted lesion from the initial position relocation is obtained. Then the BLES stereotactic biopsy is performed. Through a small skin cut, the end-sharp probe is navigated through the breast tissue to the targeted area and, using radiofrequency (RF), an intact piece of breast specimen is retrieved and harvested inside the BLES basket at the end of the probe, which separates and removes the tissue. Due to RF application, a patient return electrode is applied to the upper back on the contralateral side of the breast to be biopsied.

After the biopsy, a radiographic image of the removed specimen is performed to assess the presence of the target lesion and a clip marker is positioned in the cavity through the biopsy channel. The sample is then placed in formalin and sent to the pathology department for histopathology test.

The patient follows the post biopsy treatment with local compression, dressing the skin incision site and applying a compressive bandage. Post biopsy control mammogram of the breast is performed to show the correct placement of the clip marker at the cavity site and the presence or absence of residual calcifications and any immediate biopsy complications. A post procedure clinical follow up appointment 48 hours after the biopsy is then booked to check the healing of the skin incision and deal with any complications, such as hematoma or infection.

The histopathology analysis of the specimen consists of the macroscopic measurement of the size of the BLES biopsy specimen and inking of the margins of the specimen. Microscopically, the presence and the type of cancer or cell atypia, the size of the included lesion and its distance from the margins (mm) are mentioned in all pathology reports. The distance of the lesion from the margins mentioned in the pathology result is the shortest distance of the lesion from the ink of the margins. Thermal artefacts if present and significant for the pathology diagnosis are also noted in the final report. Regarding cancers, the grade (G1-G3, high, intermediate and low grades DCIS) and the molecular type (luminal cancers, HER2 positive cancers and triple negative cancers)
are reported. In the surgical results, the presence or absence of the cavity from the previous BLES biopsy and any residual disease (malignancy or benign high-risk lesion) around the cavity are mentioned in the report. The size (in mm) of the residual disease is also mentioned.

The statistical analysis parameters were as follows: A) the mean values and the respective standard deviations were used to describe scale measurements such as the mammographic size and the margins in mm; B) frequencies and percentages were used for categorical variables such as BLES and surgical results and the lesion types; C) the mammographic size, the distance (mm) of the targeted lesion from the margins of the specimen, the grade and the molecular type of the cancers and the presence of comedo necrosis were the imaging and histopathology criteria that were statistically analyzed for the purposes of the study. For statistical reasons, the high, intermediate, and low grades DCIS were mentioned as grade 3, 2 and 1, respectively along with the grade of the invasive cancers. The statistical analysis of the cancers and the high risk lesions was performed separately (the results are reported for 90 cancers and 29 high risk lesions, separately). Mann Whitney test, Pearsons Chi-Square and Fisher’s test were used to assess statistical differences and associations. ROC analysis was used for the estimation of effective cut off sizes of the variants and their associated sensitivity and specificity; D) SPSS v22.0 Software was used for the analysis and the statistical significance was set at 0.05.

Results

There were 90 confirmed malignant cases and 29 confirmed high-risk lesions with cell atypia with subsequent surgery. The main characteristics of the cancers are presented in Table 1.

The high-risk lesions included in the study were mainly flat epithelial hyperplasia (13); lobular neoplasia type 1 and 2 (8); atypical ductal hyperplasia (4), papillomas with cell atypia (3) and mucocele like lesion with atypia (1).

BLES excision was achieved in 31/90 (34.4%) cancers and in 23/29 (79.3%) high risk lesions with cell atypia. From these cancers, 25 were pure DCIS, 3 were pure invasive cancers (1 tubular, 1 IDC and 1 ILC) and 3 were invasive cancers with additional DCIS.

There was a statistically significant association between the initial mammographic size and the achievement of excision (Mann Whitney test, p<0.001). The size of the lesions that were excised was significantly smaller (mean size=6.32 mm) than the size of the lesions that were not excised (mean size 20.14 mm) (Table 2, Figure 1). ROC analysis showed a cut off size of 14 mm over which none of the tumors were excised (sensitivity 100%, specificity 39% and area under curve (AUC) 0.892) (Figure 1). The success rate of excision was increased with the decrease in the size of the tumor. Specifically, 57.4% cases were excised with a size smaller than 14 mm, 71.8% at a cut off size of 8 mm (sensitivity 80.6%, specificity 81.4%) and 95.7% at a cut off size of 4.5 mm (sensitivity 29%, specificity 98.3%).

Table 1. The mean main characteristics of the tumors and the relevant percentages

| Tumour Characteristics | Number | Percentage |
|------------------------|--------|------------|
| DCIS                   | 72/90  | 80%        |
| DCIS +Microinvasion    | 10/72  | 20%        |
| DCIS + Invasion        | 13/72  | 45.5%      |
| Intraductal            | 12     | 23.3%      |
| Lobular                | 3      | 20%        |
| Tubular                | 2      | 45.5%      |
| Papillary              | 1      | 20%        |
| Comedo                 | 21/90  | 76.6%      |
| Grade 1                | 23/90  | 28.8%      |
| Grade 2                | 41/90  | 39%        |
| Grade 3                | 26/90  | 28.8%      |
| Luminal                | 69/90  | 76.6%      |
| Her 2 Positive         | 18/90  | 28.8%      |
| Triple Negative        | 3/90   | 3.3%       |
| Mean Size (N=90)       | 15.38 mm (st. dev.= 13.579 mm, range 3-78 mm) |

Table 2. The mean mammographic size of the cancers that were excised and the cancers that were not excised using the BLES device

| Mean Mammographic size / std deviation | Number of cases n=90 |
|---------------------------------------|----------------------|
| 6.32mm / 2.737mm                      | Excised cases n=31   |
| 20.14 mm/ 14.568mm                    | Not excised cases n=59 |
There was a statistically significant association between the distance of the tumors from the BLES specimen margins and the achievement of excision. In cases where the margins were disease-free the achievement of excision was 67.57% (25 cases) and in cases where the margins were involved was 11.32% (6 cases) (Pearson Chi-Square test, p<0.001). ROC analysis showed that at a cut off distance of 0.75 mm the specificity was 96.6%, the sensitivity was 35.5% and the AUC was 0.816 (Table 3, Figure 2).

There was a statistically significant association between the presence of comedo necrosis and the failure of excision (Pearson Chi-Square, p=0.006). In comedo cases, the failure of excision was higher (90.48%, 19 cases) whereas in cases where comedo necrosis was absent the failure of complete removal was lower (57.97%, 40 cases) (Table 4, Figure 3).

**Table 3.** Number of tumors with involved BLES specimen margins and with disease-free BLES specimen margins and the achievement or failure of BLES removal according to the final surgical result.

| BLES specimen margins | Excision on surgical specimen | Residual disease on surgical specimen |
|-----------------------|-------------------------------|--------------------------------------|
| Margins involved      | 6                             | 47                                   |
| Disease free margins  | 25                            | 12                                   |

**Table 4.** Comedo necrosis cases (present/not present) and the achievement or failure of BLES excision in the final surgical result (excision/residual disease)

| Comedo necrosis cases | BLES excision | Residual disease |
|-----------------------|---------------|------------------|
| Present               | 2             | 19               |
| Not present           | 29            | 40               |
There was a statistically significant association between the grade of the cancers and the achievement of complete removal (Pearson Chi-Square, \( p=0.021 \)). In G3/high grade DCIS cases, the failure of excision was statistically higher (80.77%, 21 cases) whereas in G1/low grade DCIS cases, the failure was lower (43.48%, 10 cases) (Table 5, Figure 4).

No statistical association was seen between the molecular type and the BLES excision (Pearson Chi-Square, \( p=0.797 \)) (Table 6).

The only statistically significant finding for the achievement of excision of the high-risk lesions was the distance of the lesion from the specimen margins (\( p=0.041 \) Mann Whitney test). Also, 94.7% of the cases (18/19 lesions) were removed when the distance was over 1 mm, whereas 50% of the cases (5/10 lesions) were removed when the distance was 0.5 mm or 0 mm from the specimen margins.

The underestimation rate of cancers was 15.5% (14/90 cases); 7.7% (7/90 cases) was the underestimation rate of DCIS to invasive cancer; 3.3% (3/90) was the underestimation rate of DCIS to microinvasion; and 4.4% (4/90) was the underestimation rate of microinvasion to invasive cancer. No underestimation rate was found regarding the high-risk lesions. The complication rate was 8.75%.

Figures 5 and 6 illustrate cases of calcifications found to be DCIS and ILC respectively, which were completely removed using the BLES device (Figures 5, 6).

### Table 5. Correlation of the grade of the tumor (I-III) and the achievement or failure of BLES excision according to the final surgical result (excision/residual disease)

| Grade of tumors | BLES excision | Residual disease |
|-----------------|---------------|-----------------|
| I               | 13            | 10              |
| II              | 13            | 28              |
| III             | 5             | 21              |

### Table 6. Correlation of the molecular type of the cancers and the achievement or failure of BLES removal according to the final surgical result (excised/residual disease)

| Molecular type  | BLES excision | Residual disease |
|-----------------|---------------|-----------------|
| Luminal         | 25            | 44              |
| HER2 positive   | 5             | 13              |
| Triple negative | 1             | 2               |
**Figure 5.** Mediolateral view (MLO) of the left breast shows a small group of suspicious calcifications (left image). Magnification view of the group of suspicious calcifications (right upper image). BLES specimen X-RAY shows that the group of the calcifications is totally included in the specimen (right middle image). Magnification view (x 100) of the histopathology image of the BLES specimen reveals pleomorphic LCIS (DCIS) was completely removed (right lower image). Subsequent surgery confirmed the achievement of complete removal and no residual disease was found.

**Figure 6.** Right craniocaudal (CC) view shows a 5 mm cluster of suspicious calcifications (right image). Magnification view of the cluster of the calcifications (left upper image). BLES specimen X-RAY shows that the cluster of the microcalcifications is included in the specimen (right middle image). Histopathology image of the BLES specimen shows ILC with 1mm free disease margins (lower left image). No residual disease was found in the final surgical result.
Discussion

We report a study of 90 histopathologically proven cancers and 29 high risk lesions with cell atypia that underwent subsequent surgical excision. According to our results, the main criteria that could potentially be used in a clinical basis to assess BLES effectiveness in suspicious calcifications removal are the mammographic size, the distance of the lesion from the BLES specimen margins, the grade and no comedo phenotype.

We achieved complete removal of cancers in 31/90 cases (34.4%) and of high risk lesions with cell atypia in 23/29 cases (79.3%) using the intact BLES biopsy device.

Regarding cancers, the BLES success rate of excision is in agreement with previously published results with rates between 30% and 66%.5,7-10 Our study included calcifications only and no size limitation of the target lesion and this can explain the relatively low effectiveness of the method as there were lesions larger than the size that potentially the BLES probe can excise. The rationale behind this was to identify effective cut off sizes and other possible criteria, such as the grade and molecular type of the tumor, the presence of comedo necrosis and the distance of the tumor from the margins which either alone or in combination could be useful to assess the potential successful excision using the BLES device.

We found the size of the target lesion with a cut off size at 14 mm to be a major factor in excision. In cases smaller than 14mm, the success of excision was 57.4% (31/54 cases) and over that size, none of the cases was excised. Sub-analysis of smaller sizes showed a high success rate of excision of 71.4% at a cut off size of 8mm with specificity of 81.4% and in even smaller cases less than 4.5mm the excision rate was 95.7% with specificity of 98.3%. Apart from the probe size limitation, another reason that could explain the higher success rate of excision of smaller lesions is that a centrally targeted position of the tumors and thus the more accurate imaging estimation of the extent of these tumors supports the view of future targeting.

The lower grade of the tumors and the absence of comedo necrosis were found to be the criteria for complete removal. This is in agreement with results from surgical excisions that have previously shown that factors such as the high nuclear grade and the presence of comedo necrosis are associated with increased risk of residual disease in re-excisions and presence of microinvasion, respectively.19-21 In fact, in our population, 3/4 cases with microinvasion upgraded to invasion in the final result had shown comedo necrosis in the initial BLES specimen. Also, the tendency of the lower grade tumors to show higher excision rates could be potentially related to the more accurate imaging estimation of the extent of these tumors and thus the more accurate targeting.22

Regarding the high risk lesions, we found that the distance of the lesion from the specimen margins was the only criteria for the adequate excision using the BLES device and as reported previously from our department, high risk lesions were mainly removed when the distance of the lesion from the margins was over 1 mm.23 High risk lesions belong to a heterogeneous group of unknown potential of malignancy and adequate sampling with potential complete removal is the main clinical practice in order to rule out upgrading. No underestimation was found for the high-risk lesions which is the lowest of previously reported underestimations (0-9.5%)7,10,18, supporting the adequate sampling. The safe removal of the high risk lesions supports the view of future potential use of the method to excise malignant lesions as well.

The underestimation rate of the cancers was 15.5% which is in agreement with previously reported underestimations, ranging from 3.2–21.4%7,9,10; however, the underestimation of DCIS to invasion was only 7.7%. The complication rate was also low, i.e., 8.75%. Both the underestimation and the complication rates have been previously reported in a study from our department.14

There are several limitations in the study. Firstly, only cases of calcifications were included, so solid masses were not investigated. Secondly, we included all sizes of calcifications and not only small clusters that can be potentially excised with the BLES probe; therefore, further research on the performance of
BLES in small groups of calcifications is required. Thirdly, we did not analyse the subtypes of DCIS apart from the comedo necrosis as this type is the most aggressive one and, instead, we analyzed the grade of the cancers. However, both the grade of DCIS and invasive cancers were included in the same groups to simplify the statistical analysis. Fourthly, we included the data and the analysis of the high-risk lesions with cell atypia separately in this study to present an overview of the performance of BLES in excision of calcifications, thereby avoiding the mixing of the data analysis. Finally, our study is a retrospective one, so a possibility of bias cannot be excluded.

In conclusion, the small size and low grade of the cancers no comedo presence and disease free specimen margins were found to be the main criteria for suspicious calcifications excision using the BLES device, supporting the idea that potential consideration of these factors can play a role in the future clinical assessment of BLES as a possible removal tool in selected cases of suspicious calcifications.

Conflict of Interest
None.

References
1. Al-Harethee W, Theodoropoulos G, Filippakis GM, Papapanagiotou I, Matiatou M, Georgiou G, et al. Complications of percutaneous stereotactic vacuum assisted breast biopsy system utilizing radio frequency. European journal of radiology. 2013;82(4):623-6.
2. Killebrew LK, Oneson RH. Comparison of the diagnostic accuracy of a vacuum-assisted percutaneous intact specimen sampling device to a vacuum-assisted core needle sampling device for breast biopsy: initial experience. The breast journal. 2006;12(4):302-8.
3. Sie A, Bryan DC, Gaines V, Killebrew LK, Kim CH, Morrison CC, et al. Multicenter evaluation of the breast lesion excision system, a percutaneous, vacuum-assisted, intact-specimen breast biopsy device. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006;107(5):945-9.
4. Wilson R, Kavia S. Comparison of large-core vacuum-assisted breast biopsy and excision systems. Minimally Invasive Breast Biopsies. 2009:23-41.
5. Seror J-Y, Lesieur B, Scheuer-Niro B, Zerat L, Rouzier R, Uzan S. Predictive factors for complete excision and underestimation of one-pass en bloc excision of non-palpable breast lesions with the Intact® breast lesion excision system. European journal of radiology. 2012;81(4):719-24.
6. Whitworth PW, Simpson JF, Poller WR, Schonholz SM, Turner JF, Phillips RF, et al. Definitive diagnosis for high-risk breast lesions without open surgical excision: the Intact Percutaneous Excision Trial (IPET). Annals of surgical oncology. 2011;18(11):3047-52.
7. Medjhoul A, Canale S, Mathieu MC, Uzan C, Garbay JR, Domain C, et al. Breast lesion excision sample (BLES biopsy) combining stereotactic biopsy and radiofrequency: is it a safe and accurate procedure in case of BIRADS 4 and 5 breast lesions? The breast journal. 2013;19(6):590-4.
8. Milos R-I, Bernathova M, Baltzer PA, Pinker-Domenig K, Kapetas P, Rudas M, et al. The breast lesion excision system (BLES) under stereotactic guidance cannot be used as a therapeutic tool in the excision of small areas of microcalcifications in the breast. European journal of radiology. 2017;93:252-7.
9. Sanderink WB, Laarhuis BI, Strobbe LJ, Sechopoulos I, Bult P, Karssemeijer N, et al. A systematic review on the use of the breast lesion excision system in breast disease. Insights into imaging. 2019;10(1):1-12.
10. Scaperotta G, Ferranti C, Capalbo E, Paolini B, Marchesini M, Suman L, et al. Performance and role of the breast lesion excision system (BLES) in small clusters of suspicious microcalcifications. European journal of radiology. 2016;85(1):143-9.
11. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology–American Society for Radiation Oncology–American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. International Journal of Radiation Oncology*Biology*Physics. 2014;88(3):553-64.
12. Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Practical radiation oncology. 2016;6(5):287-95.
13.[Available from: http://intactmedical.com/medical.html.
14. Christou A, Koutoulidis V, Kouloucheri D, Nonni A, Zografos CG, Zografos GC. Predictive factors for breast lesion excision system (BLES) accuracy and safety in stereotactic biopsy of suspicious calcifications. The breast journal. 2020;26(3):391-8.
15. Christou A, Koutoulidis V, Kouloucheri D, Panourgias E, Nonni A, Zografos CG, et al. Performance of breast lesion excision system (BLES) in complete removal of papillomas.
presented mammographically as groups of calcifications. Clinical imaging. 2019;58:50-8.

16. Wiley EL, Diaz LK, Badve S, Morrow M. Effect of time interval on residual disease in breast cancer. The American journal of surgical pathology. 2003;27(2):194-8.

17. Chan KC, Knox WF, Sinha G, Gandhi A, Barr L, Baiddam AD, et al. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer. 2001;91(1):9-16.

18. Rodriguez N, Diaz LK, Wiley EL. Predictors of residual disease in repeat excisions for lumpectomies with margins less than 0.1 cm. Clinical breast cancer. 2005;6(2):169-72.

19. Chagpar AB, Martin II RC, Hagendoorn LJ, Chao C, McMasters KM. Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique. The American journal of surgery. 2004;188(4):399-402.

20. Sahoo S, Recant WM, Jaskowiak N, Tong L, Heimann R. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience. The breast journal. 2005;11(4):242-7.

21. Schwartz GF, Patchefsky AS, Finklestein SD, Sohn SH, Prestipino A, Feig SA, et al. Nonpalpable in situ ductal carcinoma of the breast: predictors of multicentricity and microinvasion and implications for treatment. Archives of Surgery. 1989;124(1):29-32.

22. Allen S, Osin P, Nerurkar A. The radiological excision of high risk and malignant lesions using the INTACT breast lesion excision system. A case series with an imaging follow up of at least 5 years. European Journal of Surgical Oncology (EJSO). 2014;40(7):824-9.

23. Christou A, Koutoulidis V, Koulocheri D, Panourgias E, Nonni A, Zografos CG, et al. Role of one-pass breast lesion excision system in complete excision of high-risk breast lesions with atypia expressed as clusters of microlcalcifications. European radiology. 2019;29(6):3149-58.